PMID- 32080150
OWN - NLM
STAT- MEDLINE
DCOM- 20200302
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 8
DP  - 2020 Feb
TI  - Efficacy and safety of cefoperazone-sulbactam in empiric therapy for febrile 
      neutropenia: A systemic review and meta-analysis.
PG  - e19321
LID - 10.1097/MD.0000000000019321 [doi]
LID - e19321
AB  - PURPOSE: This meta-analysis assessed the clinical efficacy and safety of 
      cefoperazone-sulbactam for empiric therapy febrile neutropenia. METHODS: The 
      PubMed, Web of Science, EBSCO, Cochrane Library, Ovid Medline, EMBASE, and 
      ClinicalTrial.gov database were searched through May 10, 2019. Only clinical 
      trials comparing cefoperazone-sulbactam with other antibiotics for empiric 
      treatment of febrile neutropenia were included. The primary outcome was treatment 
      success without modification, and the secondary outcomes were all-cause mortality 
      and adverse events (AEs). RESULTS: Ten randomized controlled trials (RCTs) and 1 
      retrospective cohort study were included. Overall, cefoperazone-sulbactam 
      exhibited a treatment success rate similar to those of comparator drugs for the 
      treatment of febrile neutropenia (odds ratio [OR], 1.03; 95% confidence interval 
      [CI], 0.85 to 1.24, I = 0%). A similar finding was noted in pooled analysis of 10 
      RCTs (OR, 1.07; 95% CI, 0.88 to 1.30, I = 0%). Subgroup analysis showed that 
      cefoperazone-sulbactam had a treatment success rate similar to the rates of 
      comparators for adults (OR, 1.10; 95% CI, 0.88 to 1.38, I = 0%) and children (OR, 
      0.96; 95% CI, 0.63 to 1.46, I = 0%). Cefoperazone-sulbactam did not differ 
      significantly from comparators in the risks of all-cause mortality (OR, 0.96; 95% 
      CI, 0.58 to 1.58, I = 0%) or common AEs, namely rash, nausea/vomiting, and 
      superinfection. CONCLUSION: The clinical efficacy and tolerability of 
      cefoperazone-sulbactam are comparable to those of comparator drugs in the 
      treatment of febrile neutropenia.
FAU - Lan, Shao-Huan
AU  - Lan SH
AD  - School of Pharmaceutical Sciences and Medical Technology.
FAU - Chang, Shen-Peng
AU  - Chang SP
AD  - Yijia Pharmacy.
FAU - Lai, Chih-Cheng
AU  - Lai CC
AD  - Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan 
      Branch.
FAU - Lu, Li-Chin
AU  - Lu LC
AD  - School of Management, Putian University, PR China.
FAU - Tang, Hung-Jen
AU  - Tang HJ
AD  - Department of Medicine, Chi Mei Medical Center, Tainan, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Anti-Bacterial Agents)
RN  - 7U75I1278D (Cefoperazone)
RN  - S4TF6I2330 (Sulbactam)
SB  - IM
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Cefoperazone/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Febrile Neutropenia/*drug therapy
MH  - Humans
MH  - Sulbactam/*therapeutic use
PMC - PMC7034635
COIS- The authors report no conflicts of nterest.
EDAT- 2020/02/23 06:00
MHDA- 2020/03/03 06:00
PMCR- 2020/02/21
CRDT- 2020/02/22 06:00
PHST- 2020/02/22 06:00 [entrez]
PHST- 2020/02/23 06:00 [pubmed]
PHST- 2020/03/03 06:00 [medline]
PHST- 2020/02/21 00:00 [pmc-release]
AID - 00005792-202002210-00080 [pii]
AID - MD-D-19-06606 [pii]
AID - 10.1097/MD.0000000000019321 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Feb;99(8):e19321. doi: 10.1097/MD.0000000000019321.